Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival [0.03%]
MONALEESA-3研究：瑞博西利联合氟维司群治疗绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌的最终分析——总生存期更新
D J Slamon,P Neven,S Chia et al.
D J Slamon et al.
Background: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-nega...
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830] [0.03%]
阿代曲妥珠单抗恩美他西（TDM1）治疗HER2扩增肿瘤患者（除乳腺癌和胃食管交界腺癌外）：NCI-MATCH试验（EAY131方案Q）的结果：[Ann Oncol 30 (2019) 1821-1830]的勘误公告
K L Jhaveri,X V Wang,V Makker et al.
K L Jhaveri et al.
Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231] [0.03%]
对“仅基于肿瘤的测序聚焦生殖细胞分析：欧洲医学肿瘤学会精准医学工作组的建议”的勘误:[安纳尔斯·奥弗·昂科洛吉 30 (2019) 1221-1231]
D Mandelker,M Donoghue,S Talukdar et al.
D Mandelker et al.
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159] [0.03%]
对“卵巢癌治疗的前沿：PARP抑制剂最新研究”的更新[Annals of Oncology 31 (2020) 1148-1159]校正 Erratum
M R Mirza,R L Coleman,A González-Martín et al.
M R Mirza et al.
S Peters,J Tabernero,A Cervantes et al.
S Peters et al.
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches [0.03%]
非小细胞肺癌中靶向KRAS的治疗：近期进展与新方法
M Reck,D P Carbone,M Garassino et al.
M Reck et al.
Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of RAS mutations observed in human cancers and is present...
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma [0.03%]
帕博利珠单抗与多西他赛治疗胃食管腺癌患者的Ⅲ期随机、开放标签临床试验的分子决定因素分析
K Shitara,M Özgüroğlu,Y-J Bang et al.
K Shitara et al.
Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinom...
Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab [0.03%]
在159872例癌症患者中的真实世界患病率表明，TMB-H可用于定义转移性实体瘤并接受帕博利珠单抗治疗的临床实用性
D Fabrizio,R Cristescu,L Albacker et al.
D Fabrizio et al.
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust [0.03%]
基因表达特征用于调整乳腺癌辅助化疗：更强的证据，更高的信任度
M J Piccart,K Kalinsky,R Gray et al.
M J Piccart et al.
Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study [0.03%]
KATHERINE研究中新辅助治疗后残余侵袭性乳腺癌的特征
E P Mamounas
E P Mamounas